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Abstract
Background: Acute gastroenteritis (AGE) is the leading cause of illness among returning travelers seeking medical
care. Multiple types of enteric pathogens can cause travel-acquired AGE and, while bacterial pathogens have
a predominant role, the importance of viruses, such as norovirus, is increasingly recognized. There is a lack of
information on travel-acquired norovirus incidence among symptomatic and asymptomatic individuals irrespective
of healthcare-seeking behavior. Our aim is to estimate the incidence of travel-acquired AGE due to norovirus and to
characterize the burden of disease among international travelers from the United States and Europe.
Methods: We describe a prospective cohort study implemented in five US and European sites to estimate the role of
AGE due to norovirus among adult international travelers. We enrolled individuals aged 18 years and older
who are traveling to regions of moderate-high risk of AGE, or via cruise ship with an international port stop,
with a trip duration of 3–15 days. The study will generate a wide range of health and travel-related data for
pre-, during, and up to 6-months post-travel. We will identify laboratory-confirmed travel-acquired norovirus
infections among both symptomatic and asymptomatic individuals from self-collected whole stool samples
tested via quantitative RT-PCR. Coinfections will be identified in a subset of travelers with AGE using a multiplex
molecular-based assay.
Discussion: This study is unique in design and breadth of data collected. The prospective collection of health
and behavioral data, as well as biologic samples from travelers irrespective of symptoms, will provide useful data
to better understand the importance of norovirus AGE among international travelers. This study will provide data
to estimate the incidence of norovirus infections and AGE and the risk of post-infectious sequelae in the 6-month
post-travel period serving as a baseline for future norovirus AGE vaccination studies. This study will contribute valuable
information to better understand the role of norovirus in travel-acquired AGE risk and the impact of these infections on
a broad set of outcomes.
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Background
Acute gastroenteritis (AGE) remains an extremely com-
mon problem among the general population and among
international travelers. In international travelers from
high- to low-resource settings, poor local sanitation and
hygiene result in transmission of enteric pathogens to
susceptible travelers [1–4]. Travelers’ diarrhea (TD)
(loose/watery stools as dominate symptom while traveling
or upon return which may include other symptoms, e.g.
abdominal cramps, nausea, vomiting) has been estimated
to occur in up to 50% of international travelers during the
initial 2 weeks of travel, depending upon study methods,
population, and destination(s) [5–9]. In AGE as a broader
term, vomiting and other acute abdominal symptoms may
be the leading symptoms with or without diarrhea. While
there is evidence that TD incidence has declined in many
regions, reported incidence rates for travelers to
resource-limited destinations still exceed 20% in the initial
2 weeks. TD results in a substantial proportion of incap-
acitation among patients, but there are limited data in
many areas [10, 11]. AGE — usually described as diarrhea
— is still the leading diagnosis of ill returning travelers
seeking medical care [12–16], as well as illness while
abroad among cohorts of travelers from high-resource
settings [17, 18].
Pathogens implicated in travel-acquired AGE include
bacteria, parasites and viruses [19–21]. Our understanding
of their individual contribution reflects endemic circulation
within the travel destination, as well as study design and
diagnostics such as choice of study population, targeted
pathogens, test performance for targeted pathogens, and
adequacy of biological sample(s) with respect to optimal
detection. Bacterial pathogens, such as Enterotoxigenic
Escherichia coli (ETEC), Enteroaggregative E. coli (EAEC),
Campylobacter jejuni (particularly in Southeast Asia), are
still identified most frequently in patients abroad with
AGE/TD, while Shigella spp. and Salmonella spp. have
lately become less frequent in on-site assessment, but may
persist in returning travelers [2, 7, 19, 20, 22–26].
Parasitic infections, such as Giardia lamblia, are gener-
ally less frequent but important causes of persistent gastro-
intestinal symptoms and may contribute a relatively larger
proportion of post-travel diarrhea cases [8, 27]. Awareness
of viral causes of travel-acquired AGE has increased along
with improved and more readily accessible diagnostic
methods. However, under-ascertainment remains a con-
cern because of limited post-travel healthcare-seeking
behavior due to factors such as differences in the clinical
course of infection (i.e., relatively milder severity and
chronicity of infection) and limited viral testing in both
clinical practice and research.
Noroviruses are a leading cause of AGE globally across
all age groups and have, further, been identified as an
important cause of non-bacterial TD and AGE among
travelers [21, 28–35]. While norovirus incidence rates
among travelers are rarely reported, prevalence estimates
among individuals with TD and/or AGE range from 3 to
65% depending upon factors such as diagnostic methods,
population, and viral activity level, and co-infections are
commonly reported [7, 21, 28, 31, 36, 37]. Of the seven
recognized norovirus genogroups, genogroup I (GI) and
II (GII), cause the majority of human illness with geno-
type GII.4 responsible for most outbreaks in recent years
[38–40]. It is important to recognize that norovirus
causes vomiting in a substantial proportion of cases in
the absence of diarrhea, thus the term AGE is most rele-
vant for describing clinical symptoms related to this
infection. Further, vomiting may facilitate transmission
in contained settings, such as cruise ships, where noro-
virus has been identified as the responsible pathogen in
approximately 97% of AGE outbreaks reported to the
US-based Vessel Sanitation Program [41, 42]. Norovirus
transmission in such situations can be difficult to control
due to its low infective dose, environmental hardiness,
and multiple routes of transmission (person-to-person as
well as through contaminated food, water, and/or fomites)
[43, 44]. Sporadic/endemic norovirus-related illness is
common, as shown through cohort-based community
studies, as is viral detection in the environment [45–56].
Viral evolution and possible genotype-specific waning
of immunity following natural infection place adult
travelers, and non-travelers alike, at risk of acquiring
novel norovirus infections and subsequent illness
(withstanding the possibility for a certain level of
innate protection against specific norovirus genotypes
due to genetic determinants of histo-blood group
antigens (HBGAs) on the gut epithelial surfaces) [51,
57, 58]. Further, travelers may in fact be important
sources of global norovirus circulation and the intro-
duction of new outbreak strains to new geographic
locations [59–61].
Increased risk of post-infectious functional gastrointes-
tinal disorders (PI-FGD), particularly irritable bowel
syndrome (IBS), and other potential PI sequelae such as
rarely Guillain-Barré Syndrome, have been reported among
individuals who experienced TD or infectious diarrhea
[62–71]. While excess PI-FGD disorders occur following
both bacterial and viral enteric infections, including
norovirus, there remains some controversy regarding the
strength of the association and characterization of import-
ant host, pathogen, and environmental risk factors [72–77].
Knowledge gaps
This study seeks to address several key gaps in knowledge
related to the role of norovirus as a cause of travel-acquired
AGE. While numerous studies have documented the
important role of AGE among international travelers, a full
account of norovirus’ contribution to rates of travel-acquired
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infections, illness, healthcare utilization, daily function, costs,
and PI sequelae are needed to define targeted interventions.
Prior studies that utilized a case definition for AGE that did
not capture isolated vomiting (without diarrhea) are not
ideally suited to fully capture norovirus [42]. Many studies
reporting the potential contribution of norovirus, have
focused on ill travelers who seek post-travel healthcare
thereby missing cases with or without medical care while
abroad and may suffer from under ascertainment of viral
causes of illness due to lack of testing and/or possible clear-
ance relative to non-viral enteric pathogens [1, 6, 13, 21, 78–
80]. The existing studies do not provide sufficient data to
calculate incidence rates, describe norovirus genotype distri-
bution, the presence of co-infections, discern travel versus
non-travel-acquired infections/illnesses, nor describe traveler
characteristics associated with norovirus AGE. There is
also a lack of information on the impact of norovirus
AGE on travel plans due to illness. Location-based pro-
spective studies of gastrointestinal infections identified
and diagnostically-confirmed at pre-defined travel
destinations have provided important information on
specific populations and/or destinations, but may be
limited in generalizability, viral detection methods, or
ascertainment of pre-travel health status [2, 20, 81–84].
Our aim is to identify the burden of AGE, particularly
those cases caused by norovirus, among travelers leav-
ing from North America and Europe to areas at moder-
ate to high risk of traveler’s diarrhea by utilizing a
prospective design that enables attribution of infection
to the travel period. Data generated by this study will
be useful for guiding future development and testing of
prophylactic and/or therapeutic agents targeting
travel-acquired AGE with a particular focus on preven-
tion of norovirus AGE.
Methods / design
The norovirus travel study is a prospective multi-site cohort
study of AGE and norovirus risk among adult international
travelers from the US and Europe to areas of moderate to
high risk of traveler’s diarrhea. The overall aim of the study
is to estimate the burden of AGE caused by norovirus ac-
quired while traveling internationally.
We utilized broad eligibility criteria according to study
population characteristics such as age and health status,
as well as travel type and destination. We chose to limit
eligible trip length to 3–15 days to allow travelers to
provide post-travel stool samples within 14 days of AGE
symptom onset, when applicable, which was considered
reasonable for the detection of norovirus based on avail-
able viral shedding data [85–88]. This study design
enabled centralized diagnostic testing irrespective of
travel destination thereby increasing the diversity of
travel type and destination. This prospective study of
AGE among international travelers is the first to assess
laboratory-confirmed norovirus, based on pre- and
post-travel stool samples, among both symptomatic and
asymptomatic travelers and to assess a wide set of
burden of disease measures among travelers from
Europe and North America.
The primary study objective is to:
 estimate the incidence of AGE due to travel-
acquired norovirus.
Specific secondary research objectives are to:
 estimate the incidence of AGE due to norovirus
according to risk factors related to host (including
age, gender, underlying health conditions) and
environment (including travel origin, destination,
and mode of travel)
 estimate the incidence of medically-attended
(outpatient and inpatient) AGE due to norovirus
 estimate the proportion of AGE due to norovirus as
single and/or co-infections
 estimate the impact of AGE due to norovirus on
daily functioning and travel plans
 describe the distribution of norovirus genotypes
associated with travel, overall as well as by region of
origin and travel destination
 describe travel behaviors (including type of travel
and eating/drinking-related behavior) associated
with AGE due to norovirus, and to
 describe the clinical course (severity, duration, and
sequelae/new onset conditions) of AGE due to
norovirus, taking into consideration cofactors such
as age, underlying health conditions, and medication
use.
Exploratory research objectives are to:
 estimate the incidence of asymptomatic norovirus
infections
 estimate the direct and indirect costs associated with
AGE due to norovirus
 describe additional and secondary AGE cases among
traveling and non-traveling companions and
household members, and to
 assess the impact of delayed stool collection relative
to AGE symptom onset on the detection of
norovirus and other enteric pathogens.
This study was approved by the respective ethical
review board at each study site. Electronic case report
forms will be used within a centralized electronic data
capture system that provides an audit trail for data entry.
Remote and on-site monitoring of study implementation
is ongoing throughout the study.
Lindsay et al. BMC Infectious Diseases          (2018) 18:605 Page 3 of 13
Study population
The study population consists of individuals ≥18 years
who are residents of Germany, Switzerland or the United
States, are fluent in German and/or English, and travel
internationally for 3–15 days beginning within 120 days of
enrollment. Eligible travel includes destinations other than
Europe (defined according to the 2013 United Nations
Statistics Division Standard Country and Area Codes
Classification [89]), the United States of America, Canada,
Japan, Australia or New Zealand or cruise ship travel that
includes an international port stop in any country other
than country of origin (Fig. 1). All study participants pro-
vided signed informed consent and were received nominal
compensation for completing key study activities. Study
participants were excluded if their international travel des-
tination was to an area of high Ebola transmission at the
time of enrollment (defined by the Centers for Disease
Control and Prevention (CDC) as an area with high Ebola
transmission and concomitant “Warning Level 3, Avoid
Nonessential Travel” designation [90]).
Between March 2015 and April 2017, 1386 study par-
ticipants were enrolled from travel clinics and commu-
nity advertising located at the following five sites:
Division of Infectious Diseases and Tropical Medicine
University of Munich, Munich Germany; Travel Health
Centre at the Epidemiology, Biostatistics and Preven-
tion Institute, University of Zurich, Zurich Switzerland;
Swiss Tropical and Public Health Institute, Basel
Switzerland; Rollins School of Public Health, Emory
University, Atlanta, Georgia, United States of America;
and Kelsey Research Foundation/School of Public
Health University of Texas, Houston, Texas, United
States of America. Study-targeted travel spanned
approximately 27 months with travel destinations to
nearly every region of the world.
Data collection and follow-up of study participants
Table 1 depicts key data collection events throughout the
study. Each participant was expected to contribute be-
tween 1 and 11 month(s) of person-time. All participants
Fig. 1 Norovirus travel study: global map depicting eligible and ineligible travel destinations
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were expected to provide baseline information, daily travel
diaries, and diaries at post-travel days 2, 7, and 14, as well
as pre-travel stool samples within 7 days of travel start.
Both paper and electronic diaries were utilized in this
study. A subset of asymptomatic travelers, as well as all
travelers who experienced AGE with an onset between
day 2 of travel and day 2 post-travel, were requested to
provide a post-travel stool sample and were contacted at 3
and 6-months after their return to provide health informa-
tion post-travel.
Study participants were considered lost to follow-up if
the participant did not provide the expected study visit/
interview and/or stool sample and the site staff were
unable to reach the participant after three attempts. In
this situation, person-time was censored from the date
of the last data point provided.
Table 1 Norovirus travel study: data collection event summary
Content Data Collection Event
Pre-Travel Peri-Travel Post-Travel
Recruitment Baseline Clinical
Samplea
Daily Diary Diary
Day 2
Diary
Day 7
Diary
Day 14
Clinical
Sampleb,c
3 Month
Follow-Upc
6 Month
Follow-Upc
Eligibility ●
Demographics ●
Travel
Plans/Itinerary ● ● ● ●
Type/Reason for Travel ●
Behavior/Activities ● ●
Past 3 Months ● ● ●
Health Information
Blood Type ●
Pre-Existing Condition ●
Regular Bowel Patterns ● ● ●
Non-Specific Symptoms ● ● ● ● ● ● ●
Illness in Week Prior to Travel* ●
Medication/Vaccination
Medications ● ● ● ● ● ● ●
Vaccinations ● ● ● ● ●
Acute Gastroenteritis ● ● ● ● ● ● ●
Week Prior to Travel* ●
Medical Care ● ● ● ● ● ●
Direct and Indirect Costs ● ● ● ●
Impact on Daily Function ● ● ● ● ●
Impact on Travel Plans /
Planned Activities
● ● ●
Travel Companion and
Household Illness
●
New Onset Conditions /
Potential Post-Infectious
Sequelae
● ●
Medical Care ● ●
Direct and Indirect Costs ● ●
Impact on Daily Function ● ●
Self-Collected Stool ● ●
aPre-travel clinical sample provided within 7 days of travel start
bPost-travel clinical sample provided within 14 days of symptom onset if traveler experienced acute gastroenteritis between day 2 of travel and day 2 post-travel
or within 14 days of travel return if traveler was selected at study enrollment to provide a post-travel stool sample regardless of the absence of acute
gastroenteritis symptoms while traveling
cData collection event for a subset of the study participants including those with acute gastroenteritis between day 2 of travel and day 2 post-travel or 25% of
study participants selected at enrollment to provide post-travel stool samples and extended 3 and 6-month follow-up
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Stool sample collection and diagnostic methods
Self-collected whole stool samples were requested from
all participants within 7 days prior to travel initiation
(pre-travel stool samples). This sample was collected in
a single vial. Post-travel stool samples were requested
from all study participants who experienced any vomit-
ing and/or diarrhea between day 2 of travel and day 2
post-travel. These symptomatic individuals provided a
self-collected whole stool sample after returning from
their trip and within 14 days of symptom onset. Further,
at the time of enrollment, each site assigned every fourth
participant to the ‘asymptomatic’ subset, and these sub-
jects were asked to provide a self-collected whole stool
sample within 14 days of travel return even in the ab-
sence of vomiting and/or diarrhea. This sampling algo-
rithm assumed that 20% of such participants would, in
fact, experience such symptoms while traveling and
would be expected to provide a post-travel stool sample
within 14 days of symptom onset. All travelers who pro-
vided a post-travel stool sample were asked to provide a
single sample collected in two separate vials.
All post-travel stool samples (vial 1) were tested via
real-time quantitative reverse transcription-polymerase
chain reaction (RT-qPCR) at a central laboratory for
genogroup I and genogroup II noroviruses. If the
post-travel stool sample was RT-qPCR norovirus posi-
tive, the paired pre-travel stool sample from the study
subject was tested by the same diagnostic method. A
systematic random sample (approximately 50%) of
post-travel stool samples (vial 2) obtained from travelers
who experienced travel-acquired AGE was tested via
Luminex xTAG® Gastrointestinal Pathogen Panel (GPP)
for multiple enteric pathogens. The RT-qPCR norovirus
results will be used for the key study objectives, and
samples with norovirus positive results (using a cycle
threshold value of < 40) were tested via conventional
RT-PCR for sequence analysis of the amplicon targeting
open reading frame 1 and 2 (regions C and D). Compari-
sons between RT-qPCR and Luminex xTAG® GPP noro-
virus results will also be possible.
All stool samples were self-collected in vials without
cryopreservative and stored in refrigerated conditions
until delivery to a study site (within 24 h), at which time
they were frozen at − 70 degrees Celsius or colder.
Pre-travel stool samples and one vial of the post-travel
stool samples were shipped frozen to a central labora-
tory for RT-qPCR norovirus testing. Vial 2 of the
post-travel stool sample were available for possible
enteric pathogen testing via the Luminex xTAG® GPP, a
multiplex PCR test that can identify: Campylobacter,
Clostridium difficile Toxin A/B, Escherichia coli 0157,
Enterotoxigenic Escherichia coli (ETEC) LT/ST, Shiga-like
Toxin producing Escherichia coli (STEC) stx1/stx2, Sal-
monella, Shigella, Vibrio cholerae, Yersinia enterocolitica,
Adenovirus 40/41, Norovirus GI/GII, Rotavirus A, Giar-
dia, Cryptosporidium and Entamoeba histolytica. The
diagnostic testing strategy for norovirus and other enteric
pathogens is depicted in Figs. 2 and 3.
Case definitions and data source for key study objectives
AGE was defined as any vomiting, or three or more
loose or watery stools, or two or more loose or watery
stools plus the presence of at least one additional symp-
tom (such as fever, abdominal cramps, urgency, nausea)
within 24 h.
AGE was considered as travel-acquired and due to
norovirus if a study participant experienced AGE (as
defined above) and the AGE symptoms began between
the second day of travel and the second day after travel
return, and the pre-travel stool specimen was norovirus
negative and the post-travel stool specimen was noro-
virus positive, or if both stool specimens were norovirus
positive but the genotypes differ.
Medically-attended AGE due to norovirus (as described
above) that was acquired while traveling was identified via
self-reported healthcare contacts (see Table 1 for
collection time-points) categorized as: telephone consults,
pharmacy consults, emergency/urgent care, non-urgent
outpatient consults, home health care, traditional healer
and hospitalizations. Abstraction of personal copies of
post-travel hospitalization records provided by the study
participants were utilized when available.
The impact of travel-acquired AGE due to norovirus
(as described above) on daily function and travel plans
were similarly, identified via self-report (see Table 1 for
collection time-points). Impact on daily function, if
present, was defined according to level of incapacitation
(restriction to lodging, partially or completely bed-
ridden), as well as, perceived impact on functioning
classified as mild, moderate or severe. The impact of
travel-acquired AGE on travel plans was classified
according to change and/or cancellation of plans and the
duration of such interruption of plans.
Sample size and analysis plan
Sample size calculations were based on the normal
approximation of the binomial proportion confidence
interval to estimate proportions with 95% confidence and
1% precision. The proportion of primary interest is the
proportion of travelers with AGE due to norovirus. A
summary of sample size calculations and assumptions are
presented in Table 2. Our goal is to accurately estimate
the proportion of international travelers from US and
European-based study sites who acquire symptomatic
norovirus based on assumptions that 10 to 40% of such
travelers will experience the onset of AGE symptoms be-
tween day 2 of travel and day 2 post-travel and that 2.5 to
10% of such cases will be due to norovirus.
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Key study objectives will be analyzed according to a
formal statistical analysis plan. Data will be initially summa-
rized according to person-time, compliance with expected
study milestones (missing data, loss-to-follow-up and adher-
ence with expected timing of data provided) and descriptive
statistics related to the study cohort, their travel and health
status across follow-up time, as well as summary data
pertaining to clinical sample compliance and results. The
impact of incomplete compliance with the study protocol
will be assessed through comparison of full and partial
Fig. 2 Stool sample collection and testing strategy and algorithm for considering norovirus infection to be travel-acquired
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analytical datasets. Incident infections and AGE will take
into consideration prevalent infections and symptoms. Nor-
ovirus AGE incidence calculations will be restricted to those
individuals who have provided both a pre- and post-travel
stool sample. Stratified analyses and multivariable regression
modeling may be used to calculate incidence rates that
identify and account for potential confounding and effect
modification by key study variables. Misclassification of key
variables will be assessed through sensitivity analyses based
on alternate data sources and assumptions as appropriate.
Interpretation of statistical measures, including confidence
intervals, will be tempered with appropriate judgment and
acknowledgments of potential sources of error and limita-
tions of the analysis.
Discussion
We present a unique study design for a broad assessment
of the burden of AGE due to norovirus acquired during
international travel. We have utilized a prospective cohort
study design that identifies study participants prior to
travel and is not limited to medically-attended ill returning
travelers. This will allow incidence data to be captured for
both medically-attended and non-medically-attended
AGE events as well as description of the severity and
course of illness among study participants. The strengths
of this study are briefly described below as they relate to
the study objectives described in the methods/design
section of this manuscript.
Incidence of travel-acquired AGE due to norovirus:
Overall, according to host/environmental factors, and
medically-attended
The design of this study will allow prevalent and incident
norovirus infections to be differentiated due to the collec-
tion of pre- and post-travel whole stool samples for noro-
virus testing via RT-qPCR. The capture of AGE symptoms
before, during, and after travel will be used to establish the
timing of AGE cases. We used a broad case definition for
AGE inclusive of vomiting alone and/or TD. This is
expected to capture a substantial proportion of norovirus
cases that cause vomiting in the absence of diarrhea [42].
We will be able to assess the influence of age, gender and
underlying health on incident norovirus AGE, as well as,
the influence of travel origin/destination and mode given
the collection of demographic and health information prior
to travel. Further, we will calculate the incidence, and type
of medically-attended norovirus AGE (phone, pharmacy
consult, traditional healer, outpatient, hospitalization) based
on health care utilization data collected on travel/post-
travel diary forms.
Norovirus detection, genotype distribution, and
co-infections with other pathogens among symptomatic
and asymptomatic travelers
The use of self-reported diaries to capture illness symp-
toms along with the collection, and RT-qPCR testing,
of paired pre- and post-travel stool samples will allow
us to estimate the burden of travel-acquired AGE and
Fig. 3 Diagnostic testing strategy for enteric pathogens using the Luminex xTAG® Gastrointestinal Pathogen Panel
Table 2 Sample size calculations for estimating the proportion
of travelers with acute gastroenteritis due to norovirus
Probability
of Norovirus
given Acute
Gastroenteritis
Probability of Acute Gastroenteritis
10% 20% 30% 40%
2.5% 250 499 744 991
5% 499 991 1477 1958
10% 991 1958 2904 3830
Note: Assumptions: 1) Confidence Interval = 95%, 2) Precision = 1%, 3) Separate
Regional Estimates Based on Study Site (European and United States), and 4)
30% Over-Enrollment to Account for Incomplete Follow-Up
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the proportion of such cases that are due to norovirus.
Given the potential for asymptomatic norovirus
infections, every 4th subject enrolled in the study has
been asked to provide a post-travel stool sample (in
addition to the pre-travel sample to be provided by
all travelers) so that we can estimate norovirus inci-
dence and characterize viral outcomes in these trav-
elers [87, 91, 92].
We have designed this study to utilize a standard,
centralized RT-qPCR-based diagnostic testing algo-
rithm to identify and genotype norovirus cases.
Norovirus genotype distribution will be described overall,
as well as by travel origin and destination, which will add
valuable information for travel-acquired norovirus given
the anticipated wide range of travel destinations. In
addition to centralized norovirus testing, we will assess
the role of other common enteric pathogens in
travel-acquired AGE via regional testing of a systematic
random sample of post-travel stool samples from travelers
with AGE via Luminex xTAG® GPP. These results, in
conjunction with the RT-qPCR results, will provide an
estimate of the proportion of AGE cases that have
norovirus identified with and without additional enteric
pathogens present.
Travel behaviors associated with norovirus AGE and
impact of norovirus AGE on daily functioning and travel
plans
In addition to data collected on health status while trav-
eling, study participants will provide information related
to the type of travel, daily travel behavior, and the poten-
tial impact of AGE on daily functioning and adherence
to travel plans. Given the collection of this information,
we will be able to assess the role of traditional AGE/TD
risk factors on norovirus AGE and the impact of such
illness which will provide information to characterize
the impact of norovirus AGE among international
travelers and help guide prevention efforts.
Clinical course of norovirus AGE
Health-related data collected on travel diaries and
post-travel diaries/interviews will allow us to assess
self-reported illness severity, duration, and possible
post-infectious sequelae/new onset conditions up to
6-months post-travel (data collected during the first
2 weeks post-travel, as well as, at 3 and 6-months
post-travel). We will be able to compare potential seque-
lae for individuals with, and without, travel-acquired
norovirus AGE due to our collection of comparable data
for a subset of asymptomatic individuals. This informa-
tion on laboratory-confirmed norovirus AGE is expected
to fill a current gap in knowledge among the inter-
national travel population.
AGE cases among traveling and non-traveling
companions and household members
The inclusion of post-travel data from study participants
related to AGE symptoms among their travel compan-
ions and non-traveling household members will provide
information on the potential for secondary AGE cases
and sustained transmission of norovirus due to imported
cases. This information, while not laboratory-confirmed,
is expected to broaden our current knowledge related to
the full impact of travel-acquired norovirus AGE.
Despite the unique strengths of our study design, there
are some potential limitations and considerations with
respect to the interpretation of the ensuing results which
are summarized below. The first concerns choice of
study population and travel characteristics. The study
population is a broad composition of adults, without
health-based restrictions, attending travel and non-travel
health clinics, as well as individuals recruited through
community and college-based advertising. There were
no restrictions on type of travel, which is expected to re-
sult in a range of potential exposures. The broad inclu-
sion criteria used in this study will provide data that we
anticipate will be generalizable to a broad group of inter-
national travelers from the US and Europe.
Our choice of eligible travel destinations has both
advantages and limitations. Eligible travel destinations,
e.g., countries in regions generally considered to have
intermediate/high risk of TD among visitors, may coin-
cide with travel destinations targeted by other travel vac-
cines and/or preventive travel-related health services due
to heightened disease risk which may increase the
generalizability of our study population to international
travelers who visit travel clinics. It is, however, under-
stood that many intestinal infections, such as norovirus,
are not limited to lower-resource settings and can have
high transmission in any setting given the right condi-
tions. Further, given the restriction of travel destination
to areas with higher risk of TD, it may also be expected
that within this study population there may be a high
proportion of coinfections amongst those with and with-
out AGE. However, we may have reduced sensitivity to
detect bacterial AGE cases due to the potential delay in
collection and testing of stool samples and the absence
of culture-based detection methods. Our study will in-
clude international travel with stops in both eligible and
non-eligible destinations. While the impact of inclusion
of such travel can be accounted for in the analyses
through stratification, pooled analyses may dilute risk
estimates if there are differences between high- and
low-resource travel destinations. The inclusion of cruise
ship travel with international port stops regardless of
region may also dilute study findings in a pooled analysis
if AGE risk is low in cruise destinations that include
North America and Europe relative to other eligible
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travel destinations but can be assessed in stratified ana-
lyses. The choice of travel duration between 3 and
15 days was considered a balance between our ability to
capture a reasonable proportion of international trav-
elers and the likelihood of being exposed to and (devel-
oping symptoms of) norovirus during a given trip, the
ability to collect stool samples during the time period
when viral shedding occurs, and to reduce recall bias
[85–87, 93–98]. We recognize that many international
trips are for periods greater than 15 days and that inter-
national trip length may differ according to regional
norms and/or travel situation (e.g., expatriate, humanitar-
ian, student, and military assignments), but incidence of
AGE is considered to be highest during the first 2 weeks
of travel [11]. The use of improved detection methods on
stored/stable stool samples, such as molecular testing of
stool collected on hemoccult cards, may prove useful for
future observational and/or clinical studies [99].
We define AGE onset to be travel-acquired when
symptom onset is reported to begin between day 2 of
travel until day 2 following travel return. This time win-
dow maximizes the capture of norovirus AGE which has
an average incubation period of approximately 33 h
[100]. It is possible, however, that this time window
choice may include some domestically-acquired noro-
virus AGE cases or AGE cases caused by other enteric
pathogens with short incubation periods. Pre- and
post-travel stool sample collection timing was also se-
lected to optimize the attribution of norovirus-related
AGE to the travel period. The pre-travel sample, col-
lected within 7 days of travel start, was chosen to iden-
tify prevalent infections. The choice of timing was
selected as a balance between realistic expectations of
study participants during the busy pre-travel period and
the ability to minimize the attribution of illness occur-
ring early in a trip to infections that were acquired
before the travel began. The post-travel sample timing
was selected to be within 14 days of AGE symptom
onset. The asymptomatic subset asked to provide a
post-travel stool sample are asked to provide a
post-travel sample within 14 days of travel return.
Ideally, the stool sample would be collected as soon as
possible after symptom onset to ensure detection of the
causal pathogen if present. However, we chose to ask
study participants to provide their second stool sample
after travel return given our priority to include a broad
set of travelers and travel destinations and the difficulties
(validation and cost) related to the collection and trans-
port of stable stool samples from various destinations or
an alternate option of establishing standardized testing
facilities in all possible destinations. The collection of
post-travel stool samples after returning home was made
based on a review of the literature which suggests that
norovirus is excreted and detectable in stool for both
symptomatic and asymptomatic infections for several
weeks after infection [85, 86]. While we accounted for
30% non-compliance for provision of a post-travel stool
sample in our sample size estimates (Table 2), the possi-
bility exists that travelers with and without AGE may
differentially comply with this study requirement. This
can be assessed in our analyses, however, given the
inclusion of a subset of travelers who were asked to pro-
vide a post-travel stool sample regardless of the presence
of AGE symptoms while traveling. We chose to utilize
RT-qPCR as the gold standard for norovirus detection
while also testing a systematic random sample of
post-travel symptomatic stool specimens via Luminex
xTAG® GPP to identify possible co-infections. The multi-
plex test has the ability to detect 15 common pathogens,
has been found to have high sensitivity and specificity,
and is expected to provide valuable information on patho-
gens other than norovirus amongst the study participants
[101, 102]. There are limitations, however, as the panel
does not include all pathogens that may be encountered/
expected amongst travelers. In addition, it is expected that
the test performance may have pathogen-specific variabil-
ity associated with variability in time lag between symp-
tom onset and stool sample collection.
An additional feature of this study that warrants dis-
cussion is the use of active data collection and the
breadth of data captured. All participants were asked to
provide baseline data, daily travel diaries, and 3 separate
diary entries post-travel day 2, 7 and 14 for information
related to travel behavior and health status. Compliance
with diary provision will be assessed according to travel
and host characteristics. Post-travel data collection at 3
and 6 months will provide valuable information on new
onset health conditions, such as PI-FGD, as well as,
course of illness for those who experienced AGE and
may have extended health effects. Assessment of pro-
longed symptoms and new onset health conditions for a
period up to 6 months post-travel aligns well with the
time period assessed in prior studies, practical consider-
ations of tracking travelers over an extended period, and
appropriate time period to assess the onset of potential
complications given the biologic plausibility of many
PI-FGD [62–64, 67, 74, 103, 104]. We acknowledge that
this study protocol could have included the capture of an
additional clinical sample (e.g., saliva) to assess the influ-
ence of HBGAs and secretor status on norovirus inci-
dence, however due to practical considerations we did not
include this analysis in the current study.
Active data collection before, during, and after travel,
while intensive, will provide critical information on
health status regardless of healthcare-seeking behavior,
but this requires a high level of compliance among the
travelers. Nominal compensation was provided to partic-
ipants to counter the amount of time and effort needed
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for the expected study activities, but there remains the
potential for sub-optimal follow-up or differential
compliance.
Conclusion
AGE remains the most common illness of travelers while
abroad or returning from low-income destinations. The
contribution of norovirus, and specific norovirus genotypes,
to incident travel-acquired AGE among a diverse study
population will be investigated in this prospective study
among adults traveling internationally for 15 days or less. It
will further quantify the impact of AGE, both overall and
due to norovirus, on daily function and travel plans. The
collection of data on asymptomatic travelers and the use of
PCR-based diagnostic methods to identify incident infec-
tions will further our understanding of the causal role of
norovirus in travel-acquired infections. This study will
assess post-travel health conditions for travelers with and
without AGE. Knowledge gained will be useful for the
development, and potential future testing of, preventive
and therapeutic agents targeting travel-acquired AGE, those
cases caused by norovirus, as well as potential travel advice.
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